Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28292898 | 0.78 | NOS3 (0.44) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL4331730 | 0.78 | NOS3 (0.33) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL9753602 | 0.78 | NOS3 (0.44) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL4928726 | 0.78 | ALDH1A1 (0.35) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL38665080 | 0.78 | CYP3A4 (0.46) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL31096856 | 0.78 | ALDH1A1 (0.35) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL19674785 | 0.78 | CD44 (0.35) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL22332415 | 0.78 | KDM4E (0.37) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL21587311 | 0.78 | CYP3A4 (0.46) | NOS3NOS2NOS1SMN1; SMN2CYP1A2 | |
| SCHEMBL14036990 | 0.78 | TDP1 (0.46) | NOS3NOS2NOS1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118557578-A | Novel iron death inhibitor and application thereof in treatment of iron overload related diseases | 秦皓禹 | 2024-08-30 | — | — | CN | claimed |
| US-20230286932-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | claimed |
| CN-115087647-A | Synthetic method for preparing 4- (2-chloro-4-methoxy-5-methylphenyl) -N- [ (1S) -2-cyclopropyl-1- (3-fluoro-4-methylphenyl) ethyl ] -5-methyl-N-prop-2-alkynyl-1, 3-thiazol-2-amine | 纽罗克里生物科学有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2021111179-A1 | SYNTHETIC METHOD FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | claimed |
| US-20170137489-A1 | Process for the Synthesis of Therapeutic Peptides | IPSEN MANUFACTURING IRELAND LIMITED (IE) | 2017-05-18 | — | — | US | claimed |
| WO-2015181491-A1 | METHOD FOR GRAFTING OLIGOPEPTIDES INTO POROUS HYBRID MATERIALS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-12-03 | — | — | WO | claimed |
| US-20110207931-A1 | PREPARATION OF VALGANCICLOVIR AND ITS SALTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-25 | — | — | US | claimed |
| WO-2011067189-A2 | CMET INHIBITORS FOR TREATING ENDOMETRIOSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-09 | — | — | WO | claimed |
| US-20110015108-A1 | Aqueous Buffered Fluoride-Containing Etch Residue Removers and Cleaners | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2011-01-20 | — | — | US | claimed |
| US-7807613-B2 | Aqueous buffered fluoride-containing etch residue removers and cleaners | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2010-10-05 | — | — | US | claimed |
| US-6982315-B2 | Process for the preparation of carboxamides | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-03 | — | — | US | claimed |
| US-20040266637-A1 | Aqueous buffered fluoride-containing etch residue removers and cleaners | VERSUM MATERIALS US, LLC | 2004-12-30 | — | — | US | claimed |
| EP-1373190-A2 | METHOD FOR THE PRODUCTION OF CARBOXYLIC ACID AMIDES | Bayer Chemicals AG (DE) | 2004-01-02 | — | — | EP | claimed |
| US-20020193594-A1 | Process for the preparation of carboxamides | LANXESS DEUTSCHLAND GMBH (DE) | 2002-12-19 | — | — | US | claimed |
| US-6495695-B2 | A GASEOUS MIXTURE OF METHYL ETHYL KETONE, FORMALDEHYDE AND AMMONIA IS SUPPLIED OVER THE ZEOLILTE CATALYST AND REACTED IN GAS PHASE TO FORM DI, TRI OR TETRAMETHYL PYRIDINE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-12-17 | — | — | US | claimed |
| WO-2002076927-A2 | METHOD FOR THE PRODUCTION OF CARBOXYLIC ACID AMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-03 | — | — | WO | claimed |
| EP-0220204-A1 | THERMOSETTABLE POLYSTYRYLPYRIDINE PREPOLYMER TERMINATED WITH ETHYLENICALLY UNSATURATED GROUPS AND CURED PRODUCTS THEREFROM | THE DOW CHEMICAL COMPANY (US) | 1987-05-06 | — | — | EP | claimed |
| US-4658032-A | Process for producing 2,3,5-collidine and/or 2,3,5,6-tetramethylpyridine | KOEI CHEMICAL CO., LTD. (JP) | 1987-04-14 | — | — | US | claimed |
| WO-1986006386-A1 | THERMOSETTABLE POLYSTYRYLPYRIDINE PREPOLYMER TERMINATED WITH ETHYLENICALLY UNSATURATED GROUPS AND CURED PRODUCTS THEREFROM | THE DOW CHEMICAL COMPANY (US) | 1986-11-06 | — | — | WO | claimed |
| US-4575542-A | Thermosettable polystyrylpyridine prepolymer terminated with ethylenically unsaturated groups and cured products therefrom | THE DOW CHEMICAL COMPANY (US) | 1986-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193594-A1 | Process for the preparation of carboxamides | VIP, QPCT, DNPEP | NOS3 3509/4885NOS2 2933/4885NOS1 3690/4885 |
| US-20170137489-A1 | Process for the Synthesis of Therapeutic Peptides | NPEPPS, DNPEP, QPCT | NOS3 3248/4885NOS2 3293/4885NOS1 3165/4885 |
| US-20230286932-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | CYP21A2, NR5A1, HSD3B1 | NOS3 2561/4885NOS2 3003/4885NOS1 2592/4885 |
| US-20110207931-A1 | PREPARATION OF VALGANCICLOVIR AND ITS SALTS | TYMP, CYP3A7, CYP2C9 | NOS3 4625/4885NOS2 3434/4885NOS1 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.